Glostrup

• Ikervis in the Treatment of Atopic Keratoconjunctivitis - a Prospective, Randomized, Placebo-Controlled Trial Recruiting
  2022-500633-92-00 4 2025-05-09 Atopic Keratoconjunctivitis
• Additive Benefits of Semaglutide for open-AngLe glaucoma – an Opportunity for Neuroprotection (ABSALON) Recruiting
  2024-518510-87-00 6 2025-04-10 Glaucoma
• Thrombolysis in Factor Xa-inhibitors Trial (SIFT) Recruiting
  2023-509907-34-01 5 2025-03-10 acute ischemic stroke
• Long-term Extension Study for Participants with Geographic Atrophy (GA) Secondary to Age-related Macular Degeneration (AMD) in JNJ-81201887 … Recruiting
  2022-500747-21-00 4 2025-02-27 Geographic Atrophy
• Boosting recovery through excitation of arousal and awareness in comatose patients: Dose finding study (BREA2KTHROUGH DOSEFINDER) Recruiting
  2023-503617-30-02 3 2025-02-26 Coma and other disorders of consciousness due to acute traumatic and n
• Gabapentin for nerve pain in the leg from the lower back Recruiting
  2023-508537-13-01 5 2025-01-20 radicular leg pain
• Safety and efficacy of botulinum toxin A in patients with posttraumatic headache: a double-blind, randomized, placebo-controlled, parallel-g … Recruiting
  2024-515901-24-00 5 2025-01-10 Persistent post-traumatic headache
• Biomarkers in clozapine-responding schizophrenia Recruiting
  2024-515338-34-01 6 2024-10-10 Schizophrenia
• DAPHNE Recruiting
  2024-510746-14-00 6 2024-08-28 Axial Spondyloarthritis
• Safety and efficacy of botulinum toxin A (Botox) in patients with trigeminal neuralgia Recruiting
  2023-504567-17-00 5 2023-11-15 Trigeminal neuralgia
• Perineural injections of incobotulinumtoxin-A for diabetic neuropathic pain of the lower extremities: A double-blind, randomized, placebo-co … Recruiting
  2022-500727-68-01 4 2023-08-07 Diabetic neuropathic pain
• The DEXA-PSYCH Study: Dexamethasone Repurposing for Moderate to Severe Depression - A Double-Blind, Randomized, Parallel-Group, Placebo-Cont … Recruiting
  2022-501428-45-00 5 2022-12-28 Depression
• Panguian Recruiting
  2023-503474-20-00 11 2017-11-10 Rheumatoid arthritis
• A Randomized, Double-blind, Parallel-group Study to Compare Pharmacokinetics, Pharmacodynamics, Clinical Effects, and Safety between ABP 692 … Ended recruitment
  2024-512914-16-00 5 2025-09-12 Relapsing-remitting Multiple Sclerosis
• Efficacy and safety study of frexalimab (SAR441344) in adults with relapsing forms of multiple sclerosis Ended recruitment
  2024-514343-29-00 5 2024-11-19 multiple sclerosis
• Long Term Follow-Up study of Gene Therapy Trial for Patients with Retinitis Pigmentosa (progressive reduction in vision) due to a gene defec … Ended recruitment
  2024-511411-25-00 5 2022-08-25 X-Linked Retinitis Pigmentosa caused by mutations in the RPGR gene
• An international randomized clinical study, measuring safety and effectiveness of basimglurant for the treatment of pain in patients with Tr … Ended recruitment
  2024-514497-41-00 10 2022-03-24 Trigeminal neuralgia
• A Study to Evaluate Safety and Efficacy of Ocrelizumab in Comparison with Fingolimod in Children and Adolescents with Relapsing-Remitting Mu … Ended recruitment
  2023-506516-40-00 5 2022-02-11 Relapsing-Remitting Multiple Sclerosis
• Non-inferiority study of ocrelizumab and rituximab in active multiple sclerosis Ended recruitment
  2024-514287-84-00 5 2021-04-28 Multiple sclerosis
• A Study to Evaluate the Efficacy and Safety of Fenebrutinib Compared with Ocrelizumab in Adult Patients with Primary Progressive Multiple Sc … Ended recruitment
  2022-502611-10-00 5 2020-11-24 Primary Progressive Multiple Sclerosis (PPMS)
• A Study to Evaluate the Efficacy, Safety and Pharmacokinetics of a Higher Dose of Ocrelizumab in Adults With Primary Progressive Multiple Sc … Ended recruitment
  2023-506515-18-00 5 2020-10-23 Primary Progressive Multiple Sclerosis (PPMS)
• A Study to Evaluate the Efficacy, Safety and Pharmacokinetics of a Higher Dose of Ocrelizumab in Adults with Relapsing Multiple Sclerosis Ended recruitment
  2023-506467-34-00 5 2020-10-20 Relapsing Multiple Sclerosis (MS)
• An open-label extension study evaluating long-term safety, tolerability and effectiveness of ofatumumab in subjects with RMS Ended recruitment
  2023-507906-15-00 5 2019-01-30 Relapsing multiple sclerosis (RMS)
• A Study to Evaluate Effectiveness and Safety of Ocrelizumab Treatment in Patients with Progressive Multiple Sclerosis Ended recruitment
  2023-506429-13-00 5 2018-05-02 Progressive multiple sclerosis (PMS)

Showing 25–48 of 70 trials